The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
ThigpenJ.T.Chemotherapy for advanced ovarian cancer: Overview of randomized trials. Semin Oncol.2000; 27(7 suppl): 11–6.
2.
PiccartM.J., BertelsenK., JamesK.Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst.2000; 92: 699–708.
3.
McGuireW.P., HoskinsW.J., BradyM.F.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med.1996; 334: 1–6.
4.
MuggiaF.M., BralyP.S., BradyM.F.Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol.2000; 18: 106–15.
5.
National Comprehensive Cancer Network.Update of the NCCN ovarian cancer practice guidelines. Oncology.1997; 11: 95–105.
6.
BerekJ.S., BertelsenK., du BoisA.Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol.1999; 10(1 suppl): S87–S92.
7.
du BoisA., NeijtJ.P., ThigpenJ.T.First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer—a new standard of care?Ann Oncol.1999; 10(1 suppl):35–41.
8.
JudsonP.L., WatsonJ.M., GehrigP.A.Cisplatin inhibits paclitaxel-induced apop-tosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res.1999; 59: 2425–32.
9.
RowinskyE.K., GilbertM.R., McGuireW.P.Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol.1991; 9: 1692–703.
10.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
11.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56: 729–64.
12.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11: 57–89.
13.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
14.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–58.
American Society of Clinical Oncology Growth Factors Expert Panel.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000;18:3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
20.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony stimulating factors. Curr Opin Hematol.1999; 6: 145–51.
21.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
22.
SteinM.E., DrumeaK., Abu-RasmiR.Taxol-induced cellulitis after extravasation: A rarely reported event [letter]. Am J Clin Oncol.1997; 20: 540.
23.
BicherA., LevenbackC., BurkeT.W.Infusion site soft-tissue injury after paclitaxel administration. Cancer.1995; 76: 116–20.
24.
AjaniJ.A., DoddL.G., DaughertyK.Taxol-induced soft-tissue injury secondary to extravasation: Characterization by histopathology and clinical course. J Natl Cancer Inst.1994; 86: 51–3.
25.
SavareseD., BoucherJ., CoreyB.Gluta-mine treatment of paclitaxel-induced myalgias and arthralgias [letter]. J Clin Oncol.1998; 16: 3918–9.
26.
van DeventerH., BernardS.Use of gabapentin to treat taxane-induced myalgias [letter]. J Clin Oncol.1999; 17: 434–5.
27.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
28.
VempatyH., SrinivasS.Cisplatin in elderly. Proc Am Soc Clin Oncol.1999; 18: 607a.
29.
VenookA.P., EgorinM.J., RosnerG.L.Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol.1998; 16: 1811–9.
